GENE ONLINE|News &
Opinion
Blog

2022-01-28| COVID-19

New Study Suggests Vaccines Protect against Long COVID

by Daniel Ojeda
Share To

As we enter the third year of the pandemic, we are still learning about the long-term effects of Covid-19 disease. Long Covid has emerged as a debilitating and complex health problem that scientists and doctors are still trying to understand. 

Different studies have reported that between 30-60% of Covid-19 survivors experience at least one long-term symptom of the disease. As of January 27, the number of confirmed infections surpassed 360 million, this means that as many as 180 million people suffered or are suffering from long Covid.

The most common symptoms include fatigue, shortness of breath, joint and chest pain, headache, depression, and others. People with long Covid struggle with these conditions for weeks, months, and even years. Furthermore, the effects of long Covid are severe enough that they impact everyday functioning. 

Although pre-existing conditions like hypertension, obesity, and psychiatric disorders are associated with an increased risk of developing long Covid, every infected individual is at risk of developing the disease. Scientists are still trying to understand how long Covid develops. Two new studies offer some insight by revealing the amount of virus circulating in the body, as well as the presence of certain antibodies that accidentally attack healthy tissues contributing to the development of long Covid. 

Vaccines offer protection against long Covid by preventing infection in the first place. However, a new study out of Israel offers further evidence that even in breakthrough cases, vaccines offer protection against long Covid.

Related Article: A Review of Neurological Symptoms in COVID-19 Patients

Vaccines Versus Long Covid

The World Health Organization (WHO) lists ten vaccines for emergency use under the Emergency Use Authorization (EUA) including the Pfizer/BioNTech, Jonson & Johnson, and Moderna vaccines. These vaccines reduce the risk of contracting the virus and protect against severe disease and hospitalization. 

Highlighting the importance of vaccines, a new study from Bar-Ilan University in Safed, Israel showed fully vaccinated individuals are less likely to report any long Covid symptoms. 

The study enrolled over 3,000 people who were tested for SARS-CoV-2 between March 2020 and November 2021. The researchers then compared the prevalence of different symptoms in unvaccinated and vaccinated individuals. 

Overall, people that received two doses of the Pfizer/BioNTech vaccine were 36-73% less likely to report symptoms of long Covid. Vaccinated people were 54% less likely to report headaches, 64% less likely to report fatigue, and 68% less likely to report muscle pain than were their unvaccinated counterparts. 

Strikingly, vaccinated individuals and people who’d never caught SARS-CoV-2 reported symptoms at similar rates. Although this study has not been peer-reviewed, it offers an important rationale to continue with vaccination efforts. 

This study supports the results of a previous study from the UK. However, it is crucial to remember that even fully vaccinated people are still at risk of developing long Covid, and whether the vaccines are less effective at preventing the long-term effects of newer strains such as Omicron is unclear. 

Related Article: GeneOnline’s Pick: Notable Novel FDA Approved Drugs in 2021

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top